XGN logo

XGN
Exagen Inc

596
Mkt Cap
$93.02M
Volume
291,331.00
52W High
$12.23
52W Low
$2.59
PE Ratio
-4.12
XGN Fundamentals
Price
$3.64
Prev Close
$3.85
Open
$3.75
50D MA
$3.05
Beta
1.23
Avg. Volume
192,390.14
EPS (Annual)
-$0.9254
P/B
6.08
Rev/Employee
$308,217.59
$126.52
Loading...
Loading...
News
all
press releases
Exagen (XGN) Q1 2026 Earnings Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets·3d ago
News Placeholder
More News
News Placeholder
Exagen Q1 Earnings Call Highlights
Exagen Q1 Earnings Call Highlights...
Yahoo! Finance: News·4d ago
News Placeholder
The New Spec Supercycle
Momentum traders are once again crowding into emerging growth sectors as artificial intelligence infrastructure, defense modernization, advanced medical technologies, and digital asset finance combine to create one of the market’s most aggressive speculative environments in years. Several names touched new 52-week highs Monday morning alongside major technology leaders including NVIDIA (NASDAQ:NVDA). $ODYS, $KBLB, $DGXX, $BW, $XGN, $MEHA, $NVDA
24-7 Market News·5d ago
News Placeholder
Exagen Inc. (XGN) Reports Q1 Loss, Beats Revenue Estimates
Exagen (XGN) delivered earnings and revenue surprises of +29.17% and +4.57%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5d ago
News Placeholder
AtriCure (ATRC) Reports Break-Even Earnings for Q1
AtriCure (ATRC) delivered earnings and revenue surprises of +100.00% and +1.43%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·10d ago
News Placeholder
Zimmer Biomet (ZBH) Q1 Earnings and Revenues Top Estimates
Zimmer (ZBH) delivered earnings and revenue surprises of +12.57% and +1.84%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·18d ago
News Placeholder
Exagen Inc. (NASDAQ:XGN) Sees Large Decrease in Short Interest
Exagen Inc. (NASDAQ:XGN - Get Free Report) was the recipient of a large decline in short interest in April. As of April 15th, there was short interest totaling 729,740 shares, a decline of 52.5% from...
MarketBeat·20d ago
News Placeholder
Exagen Inc. (NASDAQ:XGN) Given Average Recommendation of "Moderate Buy" by Analysts
Exagen Inc. (NASDAQ:XGN - Get Free Report) has been given an average recommendation of "Moderate Buy" by the ten research firms that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating and nine have issued a buy rating on the company. The average 1...
MarketBeat·22d ago
News Placeholder
Exagen (NASDAQ:XGN) Cut to "Sell" at Wall Street Zen
Wall Street Zen downgraded shares of Exagen from a "hold" rating to a "sell" rating in a report on Sunday...
MarketBeat·27d ago
News Placeholder
Exagen Inc. (NASDAQ:XGN) Short Interest Update
Exagen Inc. (NASDAQ:XGN - Get Free Report) was the target of a large increase in short interest in March. As of March 31st, there was short interest totaling 1,534,970 shares, an increase of 34.3...
MarketBeat·1mo ago
<
1
2
...
>

Latest XGN News

View
Top Discussions